Stopping GLP-1 treatment could double risk of heart attack, stroke, or death, study finds
Stopping a GLP-1 treatment was linked to twice the combined risk of heart attack, stroke, or death for some people with type 2 diabetes, a study finds.Previous research indicated that glucagon-like peptide (GLP-1) receptor agonists can reduce heart attacks, strokes, and death in people with type 2…



,xPosition=.5,yPosition=.5;Resize=(1200,675)&impolicy=medium)








































































































,xPosition=.5,yPosition=.5;Resize=(1200,675)&impolicy=medium)





